Jounce Therapeutics, Inc.
If you purchased Jounce Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
JNCE STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE MERGER OF JOUNCE THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS
February 23, 2023.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Jounce Therapeutics, Inc. (NASDAQ: JNCE) and Redx Pharma is fair to Jounce shareholders.
The investigation concerns whether Jounce and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Jounce shareholders; and (2) disclose all material information necessary for Jounce shareholders to adequately assess and value the merger consideration. On behalf of Jounce shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.